Journal Article

A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results

  • Richardson P
  • Jagannath S
  • Moreau P
  • et al.
Blood (2012) 120(21) 202-202
DOI: 10.1182/blood.v120.21.202.202
N/ACitations
Citations of this article
35Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Abstract 202

Cite

CITATION STYLE

APA

Richardson, P. G., Jagannath, S., Moreau, P., Jakubowiak, A., Raab, M. S., Facon, T., … Lonial, S. (2012). A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results. Blood, 120(21), 202–202. https://doi.org/10.1182/blood.v120.21.202.202

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free